What's happened
Multiple major drugmakers have agreed to lower prices for Medicaid and new drugs, aligning US prices with those abroad. The deals, involving 14 companies, aim to reduce costs for low-income patients and expand access, with some companies also donating medicines and ingredients. The impact will unfold over years.
What's behind the headline?
The recent deals mark a significant shift in US pharmaceutical policy, with major drugmakers voluntarily agreeing to lower prices and increase manufacturing. These agreements could lead to substantial savings for Medicaid and uninsured patients, and foster health equity through donations of essential medicines like Eliquis. However, the actual impact remains uncertain, as Medicaid already benefits from substantial discounts, and the effect on innovation and R&D investment is unclear. The strategy reflects a pragmatic approach to avoid regulatory crackdowns, but whether it will produce lasting change depends on implementation and enforcement. The creation of the TrumpRx platform signals a move toward more direct consumer access, potentially disrupting traditional pharmacy models. Overall, these negotiations are a calculated step toward addressing high US drug costs, but their long-term effectiveness will depend on sustained policy commitment and market responses.
What the papers say
The Japan Times reports that 14 of the 17 targeted drugmakers have agreed to lower prices for Medicaid, sell discounted drugs directly to consumers, and launch new medicines at international prices. AP News highlights that companies like Amgen, Bristol Myers Squibb, and Gilead will now align US prices with those abroad, with some offering significant discounts and donating medicines such as Eliquis. The Guardian emphasizes the voluntary nature of the deals, noting that US drug prices are nearly three times higher than in other developed nations, and details the broader strategy to reduce costs through negotiations and new platforms. All sources agree that these agreements are a strategic move by the Trump administration to curb high prescription costs, with some skepticism about the long-term impact and R&D effects. The sources differ slightly in tone, with The Japan Times focusing on the progress made, AP News on the specifics of company commitments, and The Guardian on the broader policy implications and the voluntary aspect of the deals.
How we got here
In 2025, the Trump administration negotiated lower drug prices with 14 of 17 targeted pharmaceutical companies, aiming to reduce US prescription costs to match those in other wealthy nations. The effort was driven by longstanding concerns over high US drug prices, which are often nearly three times higher than in other countries. The administration's approach included direct negotiations, public pressure, and threats of tariffs, leading to voluntary agreements that include price reductions, direct-to-consumer sales platforms, and donations of critical medicines.
Go deeper
More on these topics
-
Donald John Trump is an American politician, media personality, and businessman who served as the 45th president of the United States from 2017 to 2021.
-
Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is majority owned by American shareholders. It is one of the largest pharmaceutical companies by both market capitalization and sales.
Novartis manuf
-
GSK may refer to:
GSK plc, formerly GlaxoSmithKline, a multinational pharmaceutical corporation
Galatasaray S.K., a Turkish sports club based in Istanbul
Glycogen synthase kinase
Golden State Killer, a California serial rapist and murderer
GTK Scene...
-
Bristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban (Eliquis) for people with atrial fibrillation (28% of 2024 revenues); nivolumab (Opdivo...
-
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales.
-
Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs.
-
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
-
Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.
As of February 2020, Genentech employed 13,638 people.